65,437 trials
Seborrheic Dermatitis
Primary: The Change of F-IGA From Baseline (BL) to wk 1 Will be the Primary Efficacy Variable. — -0.9; -0.6 units on a scale — p=.009
Non-Small Cell Lung Cancer
Primary: The Number of Participants Experiencing High Grade (Grades 3-4 and Grade 5) Drug-Related Select Adverse Events (AE) — 3; 0 Participants
Myopia · Hyperopia · Astigmatism
Primary: Subjective Questionnaire Response — 22; 32; 5; 3 Participants
Antibiotic-associated Diarrhea
Primary: Number of Participants With the Occurrence of Antibiotic-associated Diarrhea (AAD) - Per Protocol (PP) Population — 4; 17 Participants — p=0.007
Heat Effect
Primary: PK Parameter — 3.38; 30.75 ng/mL
Hidradenitis Suppurativa
Primary: Number of Participants With Adverse Events — 21; 16 Participants
Pain Management
Primary: Pain Reduction at 60 Minutes (Baseline Pain Score - Pain Score at 60 Minutes) — 3.95; 3.95 units on a scale
Malignant Non-small Cell Neoplasm of Lung Stage IV
Primary: Objective Response Rate — 10 percentage of participants
Type 2 Diabetes
Primary: Composite of Fasting Glucose, Glycosylated Haemoglobin c and Rates of Type 2 Diabetes Mellitus Remission. — 6; 6 Participants
Attention-Deficit/Hyperactivity Disorder · ADHD
Primary: Change From Baseline in AISRS Total Score at Day 42 — -12.1; -11.7; -12.2 score on a scale — p=0.6026
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With Moderate-to-severe Acute Exacerbation — 20; 22; 9 Participants — p=0.0276
Rabies (Healthy Volunteers)
Primary: Percentage of Participants With Rabies Virus Neutralizing Antibody (RVNA) Titers Greater Than or Equal to (>=) 0.5 International Units Per Milliliter…
Type 2 Diabetes Mellitus
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 3; 7; 9; 9 Participants
Common Variable Immunodeficiency (CVID), APDS / PASLI
Primary: Part I: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 2; 0; 2; 0 Participants
Chronic Pancreatitis · Insulin Dependent Diabetes
Primary: Quotient of Stimulated C-peptide/Glucose Level Normalized for IEQ/Kg Infused in Response to MMTT — .000000077; 0.000000079 ng/mg glucose/IEQ/kg